Medline shares are down about 3% as trading continues to re-price the stock after a major secondary offering by existing holders. The March secondary increased available supply and can weigh on near-term demand as the market absorbs the added float, especially for a relatively newly public name.

Medline priced a secondary offering on March 4, 2026 for 75,000,000 shares at $41.00 per share, and the transaction ultimately closed on March 10, 2026 after being upsized to 86,250,000 shares with the underwriters’ option fully exercised. The shares were sold by stockholders affiliated with Blackstone, Carlyle, Hellman & Friedman, and a subsidiary of the Abu Dhabi Investment Authority; Medline did not sell new shares in this secondary, meaning proceeds went to the selling holders rather than the company.

With MDLN changing hands near $42.49, the stock is hovering only modestly above the $41 secondary price, which can act as a near-term reference point for investors reassessing post-IPO valuation and liquidity. When a large block clears at a set price, it often anchors expectations for where incremental supply may emerge, amplifying downside moves on risk-off sessions or light news days.